海南医学
海南醫學
해남의학
Hainan Medical Journal
2015年
21期
3154-3156
,共3页
雷珠单抗%23G玻璃体切除%新生血管性青光眼%视网膜光凝%硅油填充
雷珠單抗%23G玻璃體切除%新生血管性青光眼%視網膜光凝%硅油填充
뢰주단항%23G파리체절제%신생혈관성청광안%시망막광응%규유전충
Ranibizumab%23G vitrectomy%Neovascular glaucoma%Panretinal photocoagulation%Silicone oil tamponade
目的 探索玻璃体腔注射雷珠单抗联合23G微创玻璃体切除、全视网膜激光光凝治疗新生血管性青光眼的效果和安全性.方法 15例(15只眼)新生血管性青光眼患者采取玻璃体腔注射雷珠单抗1.25 mg/0.05 ml,一周后观察前房角及虹膜表面新生血管消失或减退,然后行23G微创玻璃体切除、全视网膜激光光凝联合硅油填充治疗.术后6~12个月随访眼压及眼部情况.结果 手术均顺利,所有患者均未发生严重并发症.术前平均眼压(43.87±8.65) mmHg,术后一周为(24.56±4.56) mmHg,6个月时为(16.21±3.32) mmHg,12个月时为(18.21±5.32) mmHg,术后平均眼压分别与术前比较差异均具有统计学意义(P<0.05).12只眼眼压控制在正常范围,2只眼需加用2种抗青光眼药物,眼压<21 mmHg,1只眼加用抗青光眼药物后眼压>21 mmHg.结论 玻璃体腔注射雷珠单抗联合23G微创玻璃体切除、全视网膜激光光凝、硅油填充是治疗绝对期新生血管性青光眼的一种相对安全、有效的方法.
目的 探索玻璃體腔註射雷珠單抗聯閤23G微創玻璃體切除、全視網膜激光光凝治療新生血管性青光眼的效果和安全性.方法 15例(15隻眼)新生血管性青光眼患者採取玻璃體腔註射雷珠單抗1.25 mg/0.05 ml,一週後觀察前房角及虹膜錶麵新生血管消失或減退,然後行23G微創玻璃體切除、全視網膜激光光凝聯閤硅油填充治療.術後6~12箇月隨訪眼壓及眼部情況.結果 手術均順利,所有患者均未髮生嚴重併髮癥.術前平均眼壓(43.87±8.65) mmHg,術後一週為(24.56±4.56) mmHg,6箇月時為(16.21±3.32) mmHg,12箇月時為(18.21±5.32) mmHg,術後平均眼壓分彆與術前比較差異均具有統計學意義(P<0.05).12隻眼眼壓控製在正常範圍,2隻眼需加用2種抗青光眼藥物,眼壓<21 mmHg,1隻眼加用抗青光眼藥物後眼壓>21 mmHg.結論 玻璃體腔註射雷珠單抗聯閤23G微創玻璃體切除、全視網膜激光光凝、硅油填充是治療絕對期新生血管性青光眼的一種相對安全、有效的方法.
목적 탐색파리체강주사뢰주단항연합23G미창파리체절제、전시망막격광광응치료신생혈관성청광안적효과화안전성.방법 15례(15지안)신생혈관성청광안환자채취파리체강주사뢰주단항1.25 mg/0.05 ml,일주후관찰전방각급홍막표면신생혈관소실혹감퇴,연후행23G미창파리체절제、전시망막격광광응연합규유전충치료.술후6~12개월수방안압급안부정황.결과 수술균순리,소유환자균미발생엄중병발증.술전평균안압(43.87±8.65) mmHg,술후일주위(24.56±4.56) mmHg,6개월시위(16.21±3.32) mmHg,12개월시위(18.21±5.32) mmHg,술후평균안압분별여술전비교차이균구유통계학의의(P<0.05).12지안안압공제재정상범위,2지안수가용2충항청광안약물,안압<21 mmHg,1지안가용항청광안약물후안압>21 mmHg.결론 파리체강주사뢰주단항연합23G미창파리체절제、전시망막격광광응、규유전충시치료절대기신생혈관성청광안적일충상대안전、유효적방법.
Objective To explore the efficacy and safety of intravitreal injection of ranibizumab combined with 23G minimally invasive vitrectomy, panretinal photocoagulation, silicone oil in the treatment of neovascular glau-coma. Methods Fifteen patients (15 eyes) with absolute neovascular glaucoma were enrolled in the study, which were treated with intravitreal injection of ranibizumb 1.25 mg/0.05 ml, followed by 23G minimally invasive vitrecto-my and panretinal photocoagulation after a week based on the observation of disappear or decline of anterior chamber angle and the surface of iris neovascularization. All the patients received silicone oil tamponade. Postoperative intraoc-ular pressure (IOP) and ocular situation during the follow-up of 6~12 months were observed. Results The operation was successful in all the patients, with no severe complication occurred. The mean IOP level was (43.87±8.65) mmHg before the operation, (24.56 ± 4.56) mmHg one week after operation, (16.21 ± 3.32) mmHg 6 months after operation, (18.21±5.32) mmHg 12 months after operation, and the levels after operation were significantly lower than that before operation (P<0.01). Twelve eyes had the IOP controlled in the normal range, 2 eyes applied 2 kinds of anti-glauco-ma drugs and had the IOP controlled<21 mmHg, and 1 eye applied anti-glaucoma drug and had the IOP still IOP>21 mmHg. Conclusion Intravitreal injection of ranibizumb combined with 23G minimally invasive vitrectomy, pan-retinal photocoagulation, silicone oil tamponade is a relatively safe, effective method for the treatment of absolute phase of neovascular glaucoma.
